Join to access to all OVN content. Join for Free

Results for 'networking importance'

...
Partner Avatar Tom Caravela
Job Search Checklist for Aspiring Medical Science Liaisons

May 16th • 2 mins read

...
Partner Avatar Tom Caravela
MSL Hiring and Recruitment: 5 Ways to Support Diversity and Inclusion

May 18th • 2 mins read

...
Partner Avatar Tom Caravela
10 Ways to Make an Impact on a Phone Interview

Apr 8th • 1 min read

...
Partner Avatar Bridget Rasmusson
6 Tips to Ace Your Next MSL Interview!

Sep 27th • 1 min read

...
Partner Avatar Tom Caravela
Combatting the “Summer Slow Down"​ – MSL Job Search Tips for Slower Months

Jun 22nd • 2 mins read

...
Partner Avatar Tom Caravela
MSL Evolution: New Trends and Titles That May Emerge

Apr 4th • 1 min read

...
Partner Avatar Tom Caravela
MSL People Skills: Top 10 Tips for Better Engagement

Apr 19th • 8 mins read

...
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Apr 19th • 8 mins read

...
OVN Avatar Mark Verrill, Paul Declerck, Sibylle Loibl, Jake Lee & Javier Cortes
The rise of oncology biosimilars: from process to promise

Aug 22nd • 18 mins read

...
OVN Avatar YuQian Liu, PharmD
Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems

Jul 6th • 25 mins read

...
OVN Avatar Natansh D. Modi, BPharm; Ahmad Y. Abuhelwa, PhD; Ross A. McKinnon, PhD
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration

Jul 27th • 20 mins read

...
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Mar 31st • 30 mins read

...
Partner Avatar Envision Pharma Group
Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

May 8th • 5 mins read

...
Partner Avatar Envision Pharma Group
Medical affairs: The power behind redefining commercialization

Aug 1st • 3 mins read

...
Partner Avatar Envision Pharma Group
Empowering people to drive medical affairs performance with AI

Aug 13th • 5 mins read

...
OVN Avatar E Dawn Flick, Howard R Terebelo, Susan Fish, Amani Kitali, Vrinda Mahajan, Melissa Nifenecker, Kristen Sullivan, Paul Thaler, Sarah Ussery, David L Grinblatt
The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research

Jun 6th • 8 mins read

...
OVN Avatar Stephanie Faucette, Santosh Wagh, Ashit Trivedi, Karthik Venkatakrishnan, Neeraj Gupta
Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development

Mar 10th • 15 mins read

...
OVN Avatar Laura A. Levit, Raymond P. Perez, David C. Smith, Richard L. Schilsky, Daniel F. Hayes, and Julie M. Vose
Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement

Feb 19th • 3 mins read

Related Topics

Loading...